The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium–glucose co-transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given:. • Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin are recommended for the prevention of HF hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or at high cardiovascular risk. • Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalization and cardiovascular death in symptomatic patients with HF and reduced ejection fraction already receiving guideline-directed medical therapy regardless of the presence of type 2 diabetes mellitus.
Heart Failure Association of the European Society of Cardiology update on sodium–glucose co-transporter 2 inhibitors in heart failure / Seferovic, P. M.; Fragasso, G.; Petrie, M.; Mullens, W.; Ferrari, R.; Thum, T.; Bauersachs, J.; Anker, S. D.; Ray, R.; Cavusoglu, Y.; Polovina, M.; Metra, M.; Ambrosio, G.; Prasad, K.; Seferovic, J.; Jhund, P. S.; Dattilo, G.; Celutkiene, J.; Piepoli, M.; Moura, B.; Chioncel, O.; Ben Gal, T.; Heymans, S.; Jaarsma, T.; Hill, L.; Lopatin, Y.; Lyon, A. R.; Ponikowski, P.; Lainscak, M.; Jankowska, E.; Mueller, C.; Cosentino, F.; Lund, L. H.; Filippatos, G. S.; Ruschitzka, F.; Coats, A. J. S.; Rosano, G. M. C.. - In: EUROPEAN JOURNAL OF HEART FAILURE. - ISSN 1388-9842. - 22:11(2020), pp. 1984-1986. [10.1002/ejhf.2026]
Heart Failure Association of the European Society of Cardiology update on sodium–glucose co-transporter 2 inhibitors in heart failure
Metra M.;
2020-01-01
Abstract
The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium–glucose co-transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given:. • Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin are recommended for the prevention of HF hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or at high cardiovascular risk. • Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalization and cardiovascular death in symptomatic patients with HF and reduced ejection fraction already receiving guideline-directed medical therapy regardless of the presence of type 2 diabetes mellitus.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
